Worldwide, prescription drug purchases made at retail pharamacies during January-July 1994 rose 4% compared to the same seven-month period of 1993 to a level of $68.2 billion, according to figures published last week by IMS International.
North American sales increased by 7% during the period to reach $29.8 billion, with sales in the USA growing 7% to $27.9 billion and Canadian retail turnover advancing 2% to $1.9 billion. Europe's top seven markets grew 2% overall to $26.1 billion during the period, although the individual markets' experiences were very varied, as cost containment measures continued to take effect.
For example, sales in Germany rose 5% to $7.5 billion, while in France they advanced only 1% to just over $7 billion, and in Italy, where cost-saving measures were introduced at the start of the year, business showed a sharp 7% decline to $4.3 billion from just under $5 billion in the first seven months of 1992. Turnover in the UK, on the other hand, showed an increase of 8% to $3.1 billion, while Spain saw business rise 3% to $2.2 billion, purchases in the Netherlands increased 5% to $968 million and sales in Belgium were up 3% to $908 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze